NeuroEndocrine Cancer Australia strengthens free specialist support for patients, carers, and families affected by neuroendocrine cancer.

SYDNEY, Aug. 28, 2026 /PRNewswire/ — NeuroEndocrine Cancer Australia (NECA) has expanded its national telehealth service to include dedicated counselling and dietitian support for the 31,000+ Australians affected by neuroendocrine cancer (NETs), a complex group of cancers that develop from specialised cells involved in producing hormones.

The new services build on NECA’s established NET Nurse program and are available free to patients, families and carers via telephone or Microsoft Teams.

“A diagnosis of neuroendocrine cancer changes everything,” said Meredith Cummins, NECA CEO. “People are navigating a disease which is poorly understood, has complex treatments and symptoms that can affect every part of daily life, often without access to specialists who understand NETs. Expanding our telehealth services means Australians can access informed, practical support wherever they live.”

Counselling Services

• Emotional and psychological support for patients, families and carers.
• Confidential counselling to help manage anxiety, uncertainty and the wider impacts of diagnosis.
• Practical strategies to support coping and wellbeing.

Dietitian Services

• Personalised nutritional guidance relevant to neuroendocrine cancer.
• Support for symptoms and nutrition challenges associated with hormonal syndromes and treatment.
• Guidance to support nutrition, health and quality of life.

“Nutrition and emotional wellbeing are among the greatest unmet needs we hear about from patients,” said Cummins. “These challenges can have a significant impact on day-to-day life during and beyond treatment. Bringing counselling and dietitian support into our telehealth service allows us to respond more holistically to what patients and families actually need.”

National Telehealth Access

The service helps address barriers faced by people who may not have access to specialist NET support locally, including those in regional and remote communities.

Services are available Monday to Friday, 9am–5pm AEST. Call 1300 287 363 or email netnurse@neuroendocrine.org.au. Support in other languages is available through TIS National on 13 14 50.

More information: neuroendocrine.org.au/your-net-care/net-nurse/

About NeuroEndocrine Cancer Australia
NeuroEndocrine Cancer Australia is the only Australian not-for-profit charity dedicated to supporting people affected by neuroendocrine cancers. NECA provides specialist nurse support, education, advocacy and research funding to improve awareness, earlier diagnosis and patient outcomes across Australia.

Media Contact:
Ciara Connolly
Media & External Affairs
ciara@neuroendocrine.org.au 

INCHEON, South Korea, Aug. 28, 2026 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company’s three-dimensional, long-term growth strategy across capacity, portfolio, and geographic expansion.

The company plans to allocate approximately KRW 2.71 trillion of the offering proceeds toward the planned acquisition of PolyPeptide Group, with the remaining approximately KRW 290 billion designated for the expansion of Bio Campus II.

In July, Samsung Biologics announced an all-cash offer to acquire PolyPeptide Group for CHF 1.46 billion (approximately KRW 2.71 trillion), a move that will broaden the company’s portfolio into peptide-based therapeutics beyond antibodies and ADCs to better meet rapidly growing global demand for diverse modalities.

Additionally, following the completion of Plant 5 at the company’s Songdo Bio Campus II in 2025, Samsung Biologics has been evaluating bringing Plants 6 through 8 online sequentially, boosting its global manufacturing capacity to 1,385,000 liters by 2032.

“Building on our position as a global top-tier CDMO, this capital raise sets the stage for our next phase of growth,” said John Rim, President and CEO of Samsung Biologics. “We are confident that executing our three-dimensional growth strategy, including the acquisition of PolyPeptide Group and the expansion of Bio Campus II, will deepen our leadership and create lasting value for shareholders.”

The rights offering comprises approximately 2,270,000 new common shares at an offering price of KRW 1,322,000 per share, representing a discount of approximately 15% from the reference price. The total funds, estimated at KRW 3 trillion, represent approximately 4.90% of the company’s market capitalization based on the previous trading day’s closing price.

The offering will be made to existing shareholders on a pro-rata basis, followed by a general public offering of any unsubscribed shares. In accordance with Korea’s Capital Markets Act, 20% of the new shares will be allocated to the company’s employee stock ownership association, with the remainder offered to shareholders proportionally.

Shareholders who do not wish to subscribe may trade their subscription rights certificates in the market. Any unsubscribed shares will be offered through a general public offering, with any remaining shares taken up by the lead underwriter.

The securities registration statement will take effect on Sept. 30, with the date for new share allocation set for Oct. 6. The subscription period for existing shareholders will take place Nov. 9–10, followed by the general public offering subscription for any unsubscribed shares on Nov. 12–13. The new shares are targeted for listing on Nov. 30.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 liters from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. The company has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., Europe, and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health.

For more information, visit https://samsungbiologics.com/.

Investor Contact

Jaewan Jun, Senior Director of Investor Relations at Samsung Biologics
jae.jun@samsung.com

Media Contact

Claire Kim, Senior Director of Marketing at Samsung Biologics
cair.kim@samsung.com

SYDNEY, Aug. 28, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it has commenced a tranched registered public offering (the “Offering“) of (i) American Depositary Shares (“ADSs”), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase ADSs (or pre-funded warrants in lieu thereof), which are exercisable immediately at an exercise price equal to 115% of the initial public offering price per ADS and accompanying Warrants and expire upon the earlier of 30 days following the Company’s Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or the five-year anniversary of issuance, and (iii) accompanying Series B Warrants to purchase ADSs (or pre-funded warrants in lieu thereof), which are exercisable immediately at an exercise price equal to 125% of the initial public offering price per ADS and accompanying Warrants and expire upon the earlier of 30 days following the Company’s HR+/HER2- data readout, expected in the first half of 2028, or the five-year anniversary of issuance. All of the securities in the Offering are to be sold by Kazia.

Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers for the proposed Offering. BTIG, Needham & Company and Laidlaw & Company are acting as co-managers for the proposed Offering. The proposed Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering.

Kazia intends to use the net proceeds from the Offering primarily to fund clinical development of paxalisib, including ongoing and planned studies in triple-negative breast cancer and HR+/HER2- breast cancer and other oncology indications, and for working capital and general corporate purposes.

The ADSs and warrants are being offered pursuant to a registration statement on Form F-3 (File No. 333-294392), which was previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”). The Offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A copy of the preliminary prospectus supplement relating to and describing the terms of the Offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com, or from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8^th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@guggenheimsecurities.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the Offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Kazia Therapeutics

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. The Company’s lead asset, paxalisib, is an investigational brain penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over 15 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM AGILE) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding the anticipated Offering and the potential gross proceeds therefrom, including the exercise of the Series A Warrants and Series B Warrants; the Company’s ability to achieve clinical milestones, including the Stage IV TNBC and HR+/HER2- data readouts that may trigger warrant exercise periods; the Company’s intended use of proceeds; and the Company’s plans for clinical development of paxalisib. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “may,” “will,” “could,” “should,” “estimates,” “projects,” “potential,” and similar expressions. These forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the Company’s ability to complete the Offering; the Company’s ability to achieve clinical milestones, including the Stage IV TNBC and HR+/HER2- data readouts that trigger warrant exercise periods; risks associated with the conduct of clinical trials and regulatory approvals; volatility in the price of the Company’s ADSs and warrants; general economic and market conditions; and the Company’s ability to maintain compliance with NASDAQ listing requirements.

For a more complete discussion of risks and uncertainties, please refer to the Company’s filings with the SEC, including the “Risk Factors” section of the Company’s most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Durable Complete Metabolic Response Ongoing Since November 2025

All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively

No Treatment-Related Serious Adverse Events Observed

SYDNEY, Aug. 28, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new data showing its lead asset, paxalisib, achieved a 100% clinical benefit rate in six evaluable patients with Stage IV triple-negative breast cancer (TNBC). Five of the six patients achieved an objective response – a measurable 30% or greater reduction in tumor burden after treatment – including one complete response and four partial responses, resulting in an objective response rate of 83 percent. The remaining patient achieved stable disease. Importantly, these results were achieved with the convenience of oral dosing and a favorable safety and tolerability profile, with no paxalisib-related serious adverse events and no grade 3 or higher hyperglycemia, stomatitis or mucositis, toxicities commonly associated with PI3K/mTOR pathway inhibition.

“Metastatic triple-negative breast cancer is one of the toughest cancers to treat. Historically, only 12 percent of patients are alive five years after diagnosis. Once a patient’s disease progresses on immunotherapy, options run out quickly,” said Dr. John Friend, CEO, Kazia Therapeutics. “Across the six evaluable patients treated, every one of them has benefited, and we haven’t seen a single serious adverse event tied to paxalisib. We’ve also demonstrated meaningful improvements in terminally exhausted T cells and drastic reductions in circulating tumor cell (CTC) clusters, providing early evidence that paxalisib may be addressing biological mechanisms associated with treatment resistance and metastasis. These results strengthen our confidence in this program as we continue enrollment in the Phase 1b trial.”

Clinical responses were observed across a broad range of metastatic disease sites, including lung, liver, bone, lymph node and central nervous system target lesions, with responses emerging as early as approximately three months post-randomization. Most notably, a 44-year-old woman with Stage IV TNBC achieved a complete metabolic response and has had no evidence of disease since November 2025. Her response has remained durable through the most recent assessment and has been accompanied by sustained and complete abolishment of CTC clusters and significant reduction in terminally exhausted CD8+ T cells, alongside overall improvement in markers of immune function.

Translational analyses demonstrated reductions in terminally exhausted CD8+ T cells across all six patients, with a median reduction of 51 percent within approximately three weeks of treatment. These cells represent a dysfunctional population of cytotoxic T cells that has lost its ability to recognize and kill cancer cells. Notably, total CD8+ T cell counts remained unchanged, which suggests that paxalisib is not eliminating these exhausted cells or replacing them with new ones. Instead, the existing cells appear to be regaining function. Blood-based simultaneous multi-modal protein, RNA and plasma profiling supported this finding, demonstrating increases in immune cell populations associated with anti-tumor activity, reductions in markers of immune exhaustion and evidence of PI3K-AKT pathway target engagement. The marker findings provide evidence of improved overall immune function across all patients.

In parallel with the immune changes, all six patients demonstrated reductions in circulating tumor cell clusters, which are aggressive groupings of tumor cells in the bloodstream associated with metastatic spread. The median reduction was 83 percent within six to seven weeks of treatment.

“Two of the biggest challenges in treating triple-negative breast cancer are the dormant cancer cells that spread through the bloodstream, and an immune system too exhausted to fight them. It’s rare to see a treatment influence both at the same time. After years of studying this disease, it’s exciting to witness this in a clinical setting. The circulating tumor cell clusters that seed new metastases are being suppressed, while the exhausted T cells needed to fight the cancer are recovering function and showing signs of immune memory, which may translate to more durable responses. These changes in the blood are tracking with what we are seeing on the scans, which suggests our liquid biopsy approach may be capturing both the tumor’s metastatic behavior and the immune system’s response to treatment in real time. It gives us a remarkable window into the disease, and we look forward to building on these findings as the trial progresses,” said Dr. Sudha Rao, Chief Scientific Officer, Kazia Therapeutics.

These early biological findings represent what may be a first-in-class effect and suggest that paxalisib’s therapeutic effect may extend beyond cytoplasmic PI3K/mTOR inhibition. The rapid and consistent biological responses observed across all evaluable patients support the hypothesis that paxalisib may exert dual influence by restoring immune function and reducing metastatic dissemination, addressing two of the greatest challenges in the treatment of triple-negative breast cancer and fundamental drivers of cancer progression.

Enrollment in the Company’s ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab (Keytruda^®) and chemotherapy in advanced metastatic TNBC is expected to be completed by July 2027, with interim clinical updates anticipated throughout 2026 and 2027.

About Kazia Therapeutics

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. The Company’s lead asset, paxalisib, is an investigational brain penetrant inhibitor of the PI3K/Akt /mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over 15 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM AGILE) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy.  Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.

Forward-Looking Statements

This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “expect,” “plan,” “believe,” “potential,” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the potential of paxalisib to provide clinical benefit, including objective responses, to patients with advanced triple-negative breast cancer; the preliminary and interim nature of the clinical, translational and biomarker data described in this announcement, and expectations regarding the durability of any observed responses; the potential for future data to alter initial and preliminary results from this early-stage clinical trial, which is based on a small number of patients and is not designed or powered to demonstrate statistical significance; the potential of paxalisib to restore anti-tumor immune function and reduce metastasis-associated circulating tumor cell clusters; the ability of translational and biomarker findings to predict clinical outcomes; the timing of completion of enrollment in, and anticipated interim updates from, the Company’s ongoing Phase 1b study of paxalisib in combination with pembrolizumab and chemotherapy in advanced metastatic TNBC; and the timing and content of future public disclosures regarding the Company’s clinical programs and development strategy.

Such statements are based on Kazia’s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with: the development of early-stage therapeutic programs; the conduct of clinical trials, including the ability to enroll patients and achieve anticipated enrollment targets; the preliminary nature of preclinical data, which may not be predictive of clinical results in humans; the preliminary nature of data from small, open-label clinical studies, which are based on a small number of patients and may not be predictive of results in a larger patient population or in later-stage or final clinical trials; risks related to regulatory approvals; risks related to Kazia’s reliance on third-party collaborators and clinical trial sites; risks related to the Company’s ability to obtain, maintain and protect its intellectual property, including the uncertainty of patent prosecution and the potential for third-party challenges; risks related to the impact of global economic conditions; and risks related to Kazia’s ability to maintain compliance with the applicable NASDAQ continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia’s Annual Report on Form 20-F filed with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.

MELBOURNE, Australia, Aug. 28, 2026 /PRNewswire/ — Global multi-omics leader Novogene is establishing its first Australian laboratory at Cabrini Health, bringing advanced genomic capabilities closer to Australian patients and researchers, reducing the wait for genomic test results that can inform cancer treatment decisions, and accelerating access to personalised treatment and precision diagnostic testing.

The joint laboratory will be strategically located within the clinical and cancer research precinct at Cabrini Malvern. Expected to open in 2027, it will become Australia’s first genomics laboratory co-located within a private hospital.

Novogene’s expansion into Australia marks a significant boost to Victoria’s precision medicine capabilities, bringing industry-leading expertise, technologies and workflows in high-throughput sequencing and advanced multi-omics.

Cabrini’s cancer services deliver approximately 30,000 treatments and 4,000 diagnoses each year, while its clinical trials program provides patients with access to innovative new therapies across approximately 100 active trials. By integrating genomic testing within the clinical environment, the laboratory is expected to enable faster turnaround from biopsy to genomic results, supporting more timely clinical decision-making and treatment initiation.

Professor Gary Richardson OAM, Group Director of Cabrini Research, Neil Beauglehall Endowed Chair of Medical Oncology Research, and medical oncologist at Cabrini Health, said the collaborative service with Novogene would deliver significant immediate and long-term benefits for patients.

“The laboratory will allow us to provide genomic results within days and connect patients more rapidly with effective treatment options, including access to clinical trials,” Professor Richardson said.

“For our cancer patients, particularly those living with rare and complex cancers, that means faster access to potentially life-saving treatments. Looking ahead, the knowledge we generate from this genomic information will help us develop new diagnostic tools and targeted therapies that will redefine how we deliver care to patients with cancer.”

The precision oncology program underpinning the new laboratory has been made possible with the support of philanthropic and government investment.

“We’ve been fortunate to secure significant investment, including a $10 million grant from the PMF Foundation and a $5 million Australian Government grant, to establish a precision oncology program that will help patients access genomic testing and personalised treatments,” Cabrini Chief Executive Sue Williams said.

“Together with Novogene, this clinically integrated service will improve the quality of our cancer services and position Cabrini as a national leader in precision oncology.”

Justin Lee, Vice President of Novogene Asia-Pacific, Middle East and Africa (AMEA), said Cabrini’s leadership in cancer care and research, together with its close connections to universities and healthcare consortia across Melbourne, made it an ideal location for Novogene’s first Australian laboratory.

“Building our first Australian laboratory at Cabrini Health represents an important milestone in Novogene’s long-term commitment to Australia,” he said. “By bringing our advanced genomics and multi-omics capabilities closer to Australian clinicians, researchers and patients, we aim to enable deeper collaboration and accelerate the translation of scientific discoveries into meaningful clinical impact. We will also strengthen our local presence by hiring and training Australian talent, establishing a robust quality management system, and fostering stronger local collaborations that leverage Australia’s world-class clinical research ecosystem.”

Dr Olivia He, Country Director of Novogene Australia, said the laboratory would strengthen Novogene’s ability to support healthcare and research partners across Australia.

“Establishing this capability in Melbourne is an important step in strengthening our presence and bringing us closer to the clinicians and researchers we work with,” she said. “It will enable faster, more responsive support and deeper collaboration as precision medicine continues to advance. With this local capability, we can better support clinical trials and pursue joint development with our Australian partners.”

About Cabrini Health

Cabrini Health is a Catholic, not-for-profit private health service located in Melbourne’s southeast. Inspired by the mission and ethic of care of the Cabrini Sisters, they have been providing quality, compassionate care to our community for more than 75 years.

Today, Cabrini employs more than 4,500 people and supports almost 100,000 episodes of care every year.  With hospitals in Malvern, Brighton and Elsternwick, Cabrini offers a comprehensive range of acute, rehabilitation, palliative care, mental health and homecare services.

Our highly-skilled staff and specialists incorporate clinical research, innovative models of care and state-of-the-art technology to deliver the best possible care and outcomes for our patients.

About Novogene

Novogene is a global provider of life sciences products and solutions, built on core strengths in multi-omics and powered by automation, advanced computing and artificial intelligence. With one of the world’s largest sequencing capacities, Novogene has processed millions of samples and supports researchers and healthcare organisations worldwide. Novogene delivers integrated solutions across the life sciences value chain, supporting precision health, clinical testing, drug development, biomanufacturing and agricultural breeding. Operating across six continents and approximately 90 countries and regions, Novogene serves more than 8,000 customers through a global network of research, production and service facilities, complemented by local expertise and support. For more information, visit amea.novogene.com.

Local agents stay local and identity never leaves the machine, while multi-layer virtualization brings Your Claude Code and your teammate’s Codex into one shared cloud Room, working in parallel in real time.

HONG KONG, Aug. 28, 2026 /PRNewswire/ — The Tutti team today opened Early Access for Tutti • VM, the industry’s first multi-user, multi-agent, real-time collaboration space and the first product to combine the best of local tools and cloud tools in one. In a Tutti • VM Room, two people’s coding agents can edit the same file at the same time without colliding. One agent can pick up another’s work with no re-briefing. A website still running on someone’s localhost can be shared with a single link. And through it all, every agent keeps running on its owner’s computer, on the subscription its owner already pays for.

Agents Got Faster. Organizations Didn’t.

Mainstream coding agents such as Claude Code and Codex run in isolated local environments. An agent takes a task, makes decisions, runs commands, and hands back a result, and only its own user sees the process. The collaboration itself runs through people. The agent summarizes to its user, the user explains to a teammate, the teammate briefs their own agent, and every hop loses information.

Unless the decisions, the file changes, and the reasoning behind them are relayed word for word, the next agent has to re-understand the project from scratch and guess what another agent was thinking from a few lines of briefing.

Most multi-agent products today have agents talk through group-chat messages or hand off sequentially under an orchestration layer. Both pass along compressed summaries. The real work stays invisible, conflicts surface only after the fact, and the more agents there are, the more rework follows. Many teams share the same experience: agents deliver noticeably faster, yet the organization as a whole does not, because the time goes into summarizing and handing off.

Three Problems Nobody Had Solved

For everyone to keep using their own machines and local tools while working in parallel in one persistent cloud workspace, three problems had to be solved first.

The strengths of local and cloud tools are mutually exclusive by design. Local-runtime tools operate directly on real projects and local files, but the machines are isolated from one another. Cloud-runtime tools are built for sharing, but they cannot use local tools, accounts, configurations, or files, and they require users to hand their identity to the platform.

Agents on different computers have no real-time channel. Context and outputs travel through slow uploads and downloads. By the time tens of megabytes of code or hundreds of megabytes of video finish syncing, parallel work has already been interrupted.

Parallel work also requires solving collaboration conflicts at the root. The ways agent commands and file operations can collide are impossible to enumerate: two collaborators installing npm dependencies at the same time, or one agent writing to a file while another moves it away. These cases go far beyond what the application-layer algorithms behind online documents can cover.

How It Works

Tutti • VM separates identity, execution, and sharing, places each where it belongs, and merges them back into one coherent agent environment.

Identity stays on the user’s computer. Claude Code and Codex keep running as local tools on the user’s physical machine. Login sessions, subscriptions, credentials, API keys, SSH keys, and corporate SSO never leave the machine, and the cloud never holds them. Agent requests still go out from the user’s real device and network identity, so model providers’ risk controls, enterprise IP allowlists, and internal services keep working.

Execution happens in a local virtualization layer. Multi-layer virtualization maps the agent’s runtime into a managed Linux environment, where the agent’s process calls and file operations are intercepted, parsed, and redirected at the kernel level. Weighing correctness, performance, and sandbox cost, the system decides whether each instruction ultimately runs on the physical machine, in the VM, or in the cloud.

Sharing and collaboration happen in the cloud Room. Only instructions that affect collaboration and outputs reach the cloud. Whatever an agent instruction issued through the Room produces, the process and the results alike, is born in the Room. There are no second copy, so even large context and outputs never travel through upload and download. To users, everyone’s live working state plays out in the Room, visible the moment it happens and ready to be built on.

On top of these three layers, Tutti • VM built its own real-time collaboration technology for agents, currently the only one of its kind in the industry, which pushes conflict handling down to the filesystem layer. The filesystem is the one language every tool speaks. Claude Code, Codex, vim, or a ten-year-old shell script will not change a line of their own code for collaboration, but they all read and write files. Built into the filesystem, collaboration becomes transparent to every tool, and thirty years of existing software “learned” to collaborate overnight. The work spans six engineering domains, from OS kernels and multi-layer virtualization to distributed consistency, collaborative editing, network and security engineering, and local-to-cloud performance optimization. Because only lightweight collaboration instructions reach the cloud, per-user sandbox cost comes to 20 to 25 percent of what a typical cloud solution costs.

Tan Zeng, Founder of Tutti said: “Think of the movie Ready Player One. Every player stays in their own separate physical space, and once the headset goes on, their avatars connect in one virtual world. Tutti • VM is the device that brings agents into that world. Local agents don’t change at all. We connect everyone’s previously isolated agents into one Room, and real-time parallel collaboration and context handoffs grow out of that.”

Inside a Room

A live shared workspace and outputs. Everyone’s local agents live in one cloud workspace, where environments, services, and dependencies are configured once. What each person is discussing with their agent, which files are being changed, and what is already done stay visible to the whole Room. Websites, videos, and documents made by agents are shared as they take shape. When a localhost site changes, collaborators see it immediately. When an 800MB video finish rendering, collaborators can watch it in full right away.

Parallel work. Different people’s local agents can build the same website or the same document at the same time, even editing the same file at the same time. Tutti • VM avoids and resolves conflicts at the filesystem layer, in the background, and there is no merge to untangle afterward.

Context handoffs and borrowed agents. Typing @ references any collaborator’s session, file, or output, and another agent continues from the current progress with no re-briefing. A collaborator can also authorize their agent for someone else to use. The borrowed agent picks up the borrower’s own context, so it works like the borrower’s own agent. Authorization can be revoked at any time, and the owner’s login never leaves their machine.

Built-in collaboration apps. Tutti • VM ships with group chat, docs, slides, image and video generation, vibe design, task management, and an agent board. Their outputs stay in the Room as well, ready to be referenced by people and agents alike.

Availability and What’s Next

Tutti • VM is free during Early Access and follows a bring-your-own-subscription model, currently supporting Claude Code and Codex, so users keep the agent subscriptions they already pay for. Seat-based plans will follow. Rooms are invite-only. Invite codes are limited and released in batches, and one code is enough to create a Room and invite collaborators. Codes are available at tutti.sh.

Tutti • VM will also offer an SDK and private enterprise deployment, giving a team’s local agents real-time collaboration, unified management of context and outputs, and organization-wide agent sharing. Updates will follow.